Liraglutide and renal outcomes in type 2 diabetes: results of the LEADER trial
Per seguirci su Facebook mettete il mi piace sulla pagina La Voce News o iscrivetevi al gruppo lavocenews.it
Of those, 49% had comorbid overweight or obesity, 61% with type 2 diabetes, and 26% with both conditions
The intent is healthy body composition and recovery support, not extreme bulking
Beyond that, the head-to-head study against tirzepatide and the REDEFINE 3 cardiovascular trial are both ongoing and expected to deliver readouts through 2026 and 2027
Patients should be informed of the potential benefits of Mounjaroincluding improved glycaemic control, weight loss, and possible cardiovascular benefitsas well as the risks, particularly in the context of having a single kidney